and Hageman factor carboxy-te_rminal fragments both formed complexes with purified C1-inhibitor, but the Hageman factor fragments appeared to have a higher affinity for the C1 -inhibitor than activated Hageman factor. Therefore, the clot-promoting activity of activated Hageman factor might be relatively unimpaired if-Hageman factor fragments are also present. Normal C1-inhibitor was cleaved by Hageman factor fragments. Clot-promoting activity was not generated in Hageman factor by exposure to Hageman factor fragments, nor was Hageman factor cleaved by Hageman factor fragments. When Hageman factor was HE PHYSIOLOGIC regulation of activated Hageman
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OONALOSON ET AL dose of danazol was cleared from body tissues within 4 days in preliminary evaluation of the drug" I'; the plasma half-life of danazol is about 15 hours.'" and that of Ci-inhibitor was about 20 hours'. and 62 hours in another. earlier study." Thcse plasmas were separated by plasmapheresis and immediately made to 0.01 mol/l. with ben7nmidine and disodium EDTA." All glassware used in purifying Hageman factor and measuring its activity had been rinsed with dichlorooctamethyltetrasiloxane.
Ci-inhibitor was isolated from normal plasma a s described previously:" in some instances. the method was modified in that QAE-Sephadex A-50 chromatography was repeated when necessary to provide the desired d e g m of purification. Ci-inhibitor prepared in this way was homogeneous in SDS-gel electrophoresis.
had a specific activity of 40 units/mg of protein.'o and as much as 70% of the starting material was recovered.
Human Hageman factor was extracted from normal plasma using minor modificationsof previous procedures." Throughout the purification proms. all test t u b a . ve~sels. and columns were either coated with Surfasil (silicone) or were made of polypropylene to avoid surface activation of the Hageman factor. Blood was drawn from normal persons initially into polypropylene bottles containing I /50 volume o f a solution of 0.5 mol/l. sodium citrate buffer. pH 5.0.0.1 mol/l. bentnmidine hydrochloride. and 100 mg Polybrene per each I0 mL of solution: buffers used during chromatography also contained t h e inhibitors (see below). After the plasma was separated by centrifugation and rendered platelet-deficient by recentrifugation at 1 2 . 0 0 0~ in a Sorvall RC-2R centrifuge for 20 minutes at 2% it was adsorbed with lysine-Sepharose to remove plasminogen and plasmin. Then the Hageman factor was isolated by sequential chromatography on columns of QAE-Sephadex A-50. DEAF cellulose. SP-Sephadex C-50. and AcA 54 Ultrogel." All buffers u . d in chromatography contained 2 mmol/L benzamidine HCI. 50 mg Polybrenc per liter. 0.1 mol/L disodium EDTA. 0.1 mol/L sodium chloride. and 0.02% sodium azide until the final SP-Sephadex C-50 chromatography step. Fractions containing 0.25 units of Mageman factor activity per milliliter or more were pooled and analyzed in SDS-polyacrylamide gels. and the specific activity of the Hageman factor was determined. The specific activity was approximately 40 coagulation units/mg protein. I unit being that amount in I .O mL of pooled normal human plasma. (This is designated a s chromatographically purified H F in legends.) Some of the Hageman factor used was purified using a S e p h a r wcorn inhibitor affinity chromatography procedure.:' where noted. just a s in preparing Hageman factor fragments. These Hageman factor preparations also gave a single band in SDS-polyacrylamide gel electrophoresis (PAGE) under reducing and nonreducing conditions (Fig I ; designated a s affinity purified HF in legends). This H F had a specific activity of 72 U/mg of protein.
Hageman factor fragments (HFf) were prepared as previously described." Fssentially. plasma depleted ofplasminogen with lysineSepharose was fractionated in a batch upon QAE-Sephadex A-50, and the Hageman factor recovered from this was then purified upon a column of SepharoK complexed with corn inhibitor." Hageman factor fragments were generated with enzite-trypsin. the insoluble enzyme removed by centrifugation. and the fragments were then isolated during gel filtration chromatography.:' Some preparations of fragments contained materials having molecular weights of 43. 35.28 Kd. and some only 28 Kd fragments (Fig 4 and Table I ).
Coagulant activity of Hageman factor was quantified using published methods" in which correction of the prolonged activated partial thromboplastin time of plasma of a person with a w e r e hereditary deficiency of Hageman factor (Hageman trait) was measured. To test column fractions for Hageman factor activity. columns were diluted 1 5 or I:20 in distilled water. or in barbitalsaline buffer. pH 7.4. containing 1% RSA. In the assay. 0.05 ml. of diluted test fractions were mixed with 0.05 mL o r a mixture of kaolin in 0.1% Centrolex-0 phospholipids and incubated together at 37°C for 2 minutes: 0.05 mL o f t tageman trait plasma was then added and incubation contined for 8 minutes. at which time 0.05 mL of 0.025 mol/L prewarmed calcium chloride was then added. The time required for fibrin formation was measured. Already activated Hageman factor in purified Hageman factor preparations was measured by testing the efTect of incubation mixtures upon the clotting time of 0.05 mL of Hageman trait plasma mixed with 0.05 mL of a I / 100 dilution of a stock cephalin preparation" and 0.05 mL of calcium chloride. but in the absence of an insoluble activating substance such a s kaolin. These assays were performed in siliconecoated Pyrex tubes (IO x 75 mm) at 37°C. There was no measurable already activated Hageman factor in the preparations used. A dilution curve of the effect of Hageman factor that had already becn activated in mixtures of RSA-sulfatides upon the cephalin clotting time of Hageman trait plasma is shown in Fig 2. Hageman factor preparations were activated at 3 7 T for 30 minutes in mixtures of RCA and brain sulfatides in silicone coated test tubes a s described by F-spana and RatnolT.': but in most experiments. a restricted population of RSA molecules at a reduced concentration (0.2%) was used to facilitate interpretation of SDS gels. The amount of S A used was found to provide optimal activation of Hageman factor during a 20 to 30 minute incubiition period. S A fractionated on a gel filtration column (AcA 44 Ultrogel) was used in the cxperiments shown in Figs 3.4.6. and UR: RSA used in the experiment shown in Fig UA was 
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RESULTS
Interactions of normal Cf-inhibitor with HFa. When purified Hageman factor (factor XII) was incubated with BSA-sulfatides, Hageman factor coagulant activity was generated, as reported earlier,'2s25 and was optimal after 20 to 30 minutes incubation with the BSA-sulfatide mixture. With the concentration of BSA used in these experiments, specific coagulant activity deteriorated when incubation was prolonged to 60 minutes or more. This may be due to the reduced amount of BSA; in an earlier report" higher concentrations of BSA were used and coagulant activity was more stable. When a solution of only 28 Kd HFf was treated with BSA sulfatides, it did not develop significant clot-promoting activity. If the HFf contained traces of uncleaved HF (75 Kd), visible in SDS-polyacrylamide gel analysis, clot-promoting activity developed during incubation with the BSA-sulfatide mixture, which doubtless reflected activation of the 75 Kd HF.
When purified Hageman factor was activated with BSAsulfatides at 37OC for 30 minutes and then mixed with purified normal Ci-inhibitor in an amount insufficient to inhibit the total amount of Hageman factor present, the clotting activity attibutable to the HFa was maximally inhibited after 20 to 30 minutes. After that, the clotting time returned towards that of the uninhibited mixture. It was possible, but unlikely, that the Ci-inhibitor might have dissociated from the HFa. Alternatively, the inhibitor might have been cleaved and inactivated by the HFa, or further activation of Hageman factor occurred in these mixtures.
When preparations of the HF and HFf were incubated together with BSA-sulfatides and the clotting times of the mixture compared with those of identically diluted mixtures of HFf and BSA-sulfatides or HF and BSA-sulfatides alone (Table l) , the clot-promoting activity that developed in mixtures of HFa and HFf was often reduced somewhat compared with that which evolved in the 75 Kd H F alone (Table 1 , lines 1, 5, and 6), probably due to dilution. When 20 wg of purified Ci-inhibitor was then added to each mixture and incubation at 37OC continued for 30 minutes (Table 1) (Fig 4) . The complexes probaqbly represent HFf with both I05 l i d and 96 Kd C'i-inhibitor.
When a mixture of HF and HFf was incuhted with RFA-sulfatidesand Ci-inhibitor was then added. the 190 Kd ltI.'a-Ci-inhibitor complex was markedly reduced in SDS-P M i E analysis. whereas the complex betwcen HFf and Cl-inhibitor remained clearly visible (Fig 3R. lane 3) . In this experiment. the tiF (35 pg) was in a molar exms with respect to the amount of HI;f used (7. Ci-inhibitor was added to the mixtures before a lrecond incubation period. the quantity of high molecular weight complex of l l f a and Ci-inhibitor (Fig 6. lanes 1 I through  13) was progressively decreased. and increasing amounts of the complex of I27 Kd (Fig 6. lanes 12 and 13) (Fig 7. lower panel) . Thus, there was no evidence that HFf "activated" H i in thew studicc. Moreover. the 75 Kd H F was not cleaved by IJFf in this experiment (Fig 7) or in several others not shown. It was possible. but unlikely. that H F a coagulant activity was not inhibited by Ci-inhibitor in mixtumcontaining HFf because the high molecular weight HFa was displaccd from its complex with Ci-inhibitor by HFf. The HFa 50 released might then exprcs its clot-promoting activity. In a n c x p r i --116 -97. 4 -67
H L ment not shown. when preformed HFa-Ci-inhibitor complexes were incubated for a n hour with less than q u i m o l a r concentrations of IIFf. as in the experiment shown in Fig 6 . the 190 Kd complex remained intact. as one would predict. T h e efkct of high concentrations of HFf on thew complexes was not tested. but the covalently bound HFa-Ci-inhibitor complex would not be predicted to be dissociable by tl Ff.
lntrractiom of dysfunctional Ci -inhihitor protrim with HFa. Ci-inhibitor activity is es.untially undetectable in serumor plasma from p e m n s with ttAXV..mdccpite the fact that all known afTecteds are hctero7ygous for this t n i t . This defect is d u e either to a n inherited deficiency of Ci-inhibitor (Fig Sa. lane 7) . which probably represents a complex with a cleaved Ci.
inhibitor. In addition. low molecular weight cleavape fragments were r e l e n d in four HFa-Type 11 inhibitor mixturcs (C i-inhibitor At. Ro. h. and H'e). as shown in Fig SA. lancs 7 and XR. lane C . The remainder of the dyfunctional Ci-inhibitor proteins failed toformcomplexczwith ItFa that were visible after SDS-pel clectrophomis. even though they did delay the clot-promoting activity of the #Fa (lnble 2. (Fig 3h. lane 5; Fig 3B. lane I ) . but the HFf seemed to have a higher afinity for Ci-inhibitor than HFa (Fig 6. lanes 1 I through 13 (Figs 3 and 4) . Moreover. the clotpromoting activity of HFa was not impaired by Ci-inhibitor when MFf wasadded to the HFa beforeCi-inhibitor ( Table  I ). The concentrations of activated forms of Hageman factor were in a molar e x m z with respect to Ci-inhibitor in these
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HF. - experiments. The diminished inhibition of #Fa coagulant activity appeared not to bc due to its displacement from complcxecuith theCi-inhibitor by the HTfprepration.and we ucre unable IO demonctrite generailon of further clotpromoting activity in the HFa preparation. or its cleavage into low molecular weight fragments by tIFf (Figs 7 and 8 ) .
Pmsibly. the reactive center of the Ci-Inhibitor is more acccwble to the low molecular weight HFf than to 72 Kd While complexes formed between HFf of three molecular weights (28, 35, and 43 Kd) and Ci-inhibitor of 155, 140, and 127 Kd (Fig 6) , an increasingly dense band of 127 Kd associated with the loss of high molecular weight complexes appeared in mixtures containing larger amounts of HFf (Fig  6) , which was confirmed in additional experiments not shown. Thus, it is likely that the lowest molecular weight HFf had the highest affinity for the Ci-inhibitor. We were unable to show that the generation of the 127 Kd complex was due to cleavage of the high molecular weight HFa already complexed with Ci-inhibitor (Fig 7) in these experiments. However, HFf did cleave Ci-inhibitor (Fig 4) . The fact that the 190 Kd complex between HFa and Ci-inhibitor was not disrupted during incubation with HFf is consistent with the apparent covalent nature of the complex.
In some of our experiments, fragments of about 40 Kd appeared during incubation of mixtures of HF and HFf. Since we did not find this cleavage fragment in other mixtures of H F and HFf (Fig 7) , H F was used as a substrate for preparations of plasma kallikrein, ClS, and streptokinaseactivated plasmin (Fig 5) in an attempt to identify the proteases that released the 40 Kd fragment. A 40 Kd fragment evolved only in the mixtures containing plasmin, suggesting that traces of unidentified contaminating plasmin had cleaved H F in some of the incubation mixtures. We did not find this fragment in kallikrein digests of the HF, as reported by Dunn and Kaplan?' but our kallikrein was purified with an affinity chromatography method,34 whereas theirs was prepared in a different manner (Fig 5) .
Ci-inhibitor is known to inhibit the activated forms of Hageman factor.' Kaplan et aI3' described low molecular weight fragments of HF (HFf), and Schreiber et all0 later reported that a preparation of HFf of about 32.5 Kd and a larger molecular weight fragment were both inhibited by normal Ci-inhibitor. RatnoP6 found that amidolytic activity of Hageman factor fragments and also of HFa activated in solutions of ellagic acid were inhibited by normal C iinhibitor.
Pixley et a136 described a 190 Kd complex between normal Ci-inhibitor and HFa that had been activated with kallikrein instead of BSA-sulfatides. Recently, Weiss et reported that Ci-inhibitor did not impair the autoactivation of a partially purified preparation of Hageman factor, but did block the products of activation. Other data derived from kinetic studies led deAgostini et and Pixley et aP6 to conclude that Ci-inhibitor is the principal inhibitor of HFf and HFa in normal plasma. Covalent complexes between HFf and Ci-inhibitor can also form in plasma, which deAgostini et identified when a preparation of HFf was added to normal plasma. The predominance of the CIinhibitor complexes with low molecular weight HFf observed in the present experiments suggests that its regulatory action may be directed principally a t the HFf, should they evolve in plasma.
We previously reported that purified Type I1 Ci-inhibitor proteins from plasmas of persons with Type I1 H A N E blocked the amidolytic propeties of HFa and HFf, with one exception (Ci-inhibitor Ri).13 One Type I1 protein ( C iinhibitor Za) had far greater inhibitory activity than normal Ci-inhibitor. In the present studies, all of these proteins inhibited the clot-promoting activity of BSA-sulfatideactivated HFa (Table 2) , although most were less effective than normal Ci-inhibitor. It may be argued that these inhibitory properties reflected the function of small amounts of normal Ci-inhibitor, which exists in plasma from all of these heterozygous patients, and which co-purifies with Type I1 Ci-inhibitors. However, the degree of inhibition of coagulant activity of HFa (Table 2) , as well as its amidolytic properties, were far in excess of that which one would predict even if 50% levels of normal Ci-inhibitor were present in preparations of Type I1 proteins, with the exception of Ci-INH-Ri. Moreover, any given preparation of a Type I1 C i-inhibitor did not provide parallel degrees of inhibition of the enzymes regulated by normal CI-inhibitor, which one would predict if the inhibition detected were, in fact, due to contaminating normal Ci-inhibitor'' ( Table 3 ). The SDSgel analyses showed that Ci-inhibitors At, Da, and We formed traces of covalent complexes with this HFa, and some cleavage of Ci-inhibitor At, Bo, Da, and We occurred as well. The Ci-inhibitor At complex was of low molecular weight (approximately 120 Kd), as if this protein had been cleaved in the process of the interaction. Cf-inhibitor At has a single amino acid substitution of His for Arg at the PI residue 444 in its reactive site.38 The same substitution has been found in Ci-INH Ri,32 and in Ci-inhibitor Da, the Arg at P, is replaced by a CYS.~' These changes all result from single base substitutions in the DNA coding for this r e~i d u e .~~.~~ Earlier observations, published in preliminary form, showed that there is a 2 Kd insertion in one of the cyanogen bromide fragments Ci-inhibitor Ta, and a deletion plus an insertion in C i -I N H We.40341 Thus, there are multiple genetic defects causing the different Type I1 inhibitors in HANE.
The complexes formed and cleavage patterns of each of these dysfunctional proteins with ClS, plasmin, kallikrein, and HFa are summarized in Table 3 , much of which was published earlier": the inhibition of the HFa shown in Table  3 represents inhibition of the amidolytic, rather than the clot-promoting, activity of this enzyme. There was significant inhibition of kallikrein and ClS13 by Type I1 Ci-inhibitors, despite the fact that they did not all form complexes that were visibly stable during SDS-gel electrophoresis. Even though C i-inhibitor Mo and Za blocked the amidolytic activity of HFa to a far greater degree than did normal Ci-inhibitor, complexes were not visible on SDS-gel electrophoretic analysis. This suggests that noncovalent binding between these dysfunctional proteins and the HFa preparation may have allowed inhibition in the enzymatic assays. The inhibition of the clot-promoting activity of the HFa used in the present experiment (Table 2) did not directly parallel the inhibition of the amidolytic activity found in earlier studiest3 (Table 3) . Even so, none of the Type I1 Ci-inhibitor preparations was totally devoid of inhibition of the coagulant action of HFa, and a t least two of them (Ci-inhibitor At and We) had normal levels of activity (Table 2 , column 4). At the
